Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Jun;8(1):e000576.
doi: 10.1136/jitc-2020-000576. Epub 2020 Jun 23.

Influence of gut microbiome on multiple myeloma: friend or foe?

Affiliations
Comment

Influence of gut microbiome on multiple myeloma: friend or foe?

Nausheen Ahmed et al. J Immunother Cancer. 2020 Jun.

Abstract

Multiple myeloma (MM) is a malignancy of terminally differentiated plasma cells, which typically evolves over time from its precursor, monoclonal gammopathy of undetermined significance. While the underlying mechanisms of this evolution remain elusive, immunomodulatory factors affecting the bone marrow (BM) microenvironment are suspected to play a role. There is an increasing evidence that the gut microbiome exerts an influence on its host's adaptive and innate immune systems, inflammatory pathways and the BM microenvironment. Dysbiosis, therefore, may impact tumorigenesis in MM. This article gives an overview of potential mechanisms by which the microbiome may influence the pathogenesis of MM, MM patients' responses to treatment and toxicities experienced by MM patients undergoing autologous transplant. It also discusses the potential role of the mycobiome in MM, a less studied component of the microbiome.

Keywords: adaptive immunity; review; systems biology; transplantation immunology; tumor microenvironment.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Comment on

References

    1. Abid MB. Could the menagerie of the gut microbiome really cure cancer? hope or hype. J Immunother Cancer 2019;7:92. 10.1186/s40425-019-0561-9 - DOI - PMC - PubMed
    1. Prabhala RH, Pelluru D, Fulciniti M, et al. . Elevated IL-17 produced by Th17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood 2010;115:5385–92. 10.1182/blood-2009-10-246660 - DOI - PMC - PubMed
    1. Kawano Y, Moschetta M, Manier S, et al. . Targeting the bone marrow microenvironment in multiple myeloma. Immunol Rev 2015;263:160–72. 10.1111/imr.12233 - DOI - PubMed
    1. Agarwal A, Ghobrial IM. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease. Clin Cancer Res 2013;19:985–94. 10.1158/1078-0432.CCR-12-2922 - DOI - PMC - PubMed
    1. Brown R, Murray A, Pope B, et al. . B7+ T cells in myeloma: an acquired marker of prior chronic antigen presentation. Leuk Lymphoma 2004;45:363–71. 10.1080/10428190310001607142 - DOI - PubMed